Advanced Study of Inflammatory Bowel diseases (ASIB)
The ASIB is an ongoing trans-omics project in inflammatory bowel disease (IBD) aiming to define molecular biosignatures to stratify patients in the context of personalized medicine. This is done in combination of a comprehensive multi-omics analysis platform and a well-defined biobank with samples from non-treated patients at debut of disease.
Our group is leading the proteomics and metabolomics analysis of colon biopsies from ASIB samples biobank. The proteomic investigation, led by Associate Professor Terkel Hansen, has revealed the deepest proteomic quantification (through TMT labelling) of colon biopsies with over 8500 proteins quantified, utilizing our in-house developed sample preparation method. The proteomic analysis is performed by nano-Liquied chromatography coupled with Thermo Fusion Lumos mass spectrometer.
The metabolomics investigation led by Associate Professor Guro Forsdahl, and performed in collaboration with the Swedish metabolomics centre (SMC) Umeå, Sweden, as well as in-house. We combine gas chromatography coupled to time-of-flight mass spectrometry (GC-TOF-MS) and ultra-high performance liquid chromatography coupled with mass spectrometry (UHPLC-MS) methods.
The ASIB study is led by Professor Jon Florholmen and senior researcher Rasmus Goll, Research group of Gastroenterology & Nutrition, Department of Gastroenterology, University Hospital of North Norway.